In an effort to enhance patient access to complex generic drugs, the Office of Generic Drugs (OGD) at the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have initiated a voluntary pilot program. This program aims to facilitate simultaneous discussions between generic drug applicants and both regulatory bodies. This initiative marks an extension of the existing Parallel Scientific Advice (PSA) program between the FDA and EMA, specifically targeting complex generics or “hybrid medicines” (a term used by EMA to describe medications akin to complex generics).
The progression of complex generic drug development stands as a pivotal aspect of the FDA’s mission to provide patients with access to safe, effective, and high-quality generic medications. The generic drug industry contends with various hurdles, including heightened competition, price erosion, and dwindling profit margins, which may deter companies from sustaining their generic drug endeavors. Despite the potential for substantial market opportunities and enhanced profit margins with complex generics, manufacturers encounter obstacles in their development due to a dearth of expertise, methodologies, or supportive evidence.
Read the full text here.
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
